Boston Scientific Corporation $BSX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

22 Apr 2026, 10:11 by Scott Moore · The Cerbat Gem

Universal Beteiligungs und Servicegesellschaft mbH grew its position in Boston Scientific Corporation (NYSE:BSX – Free Report) by 3.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,381,666 shares of the medical equipment provider’s stock after acquiring an additional 48,539 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Boston Scientific were worth $131,829,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Financial Consulate Inc. acquired a new position in shares of Boston Scientific in the third quarter worth about $25,000. Murphy & Mullick Capital Management Corp raised its position in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the second quarter worth about $26,000. United Community Bank raised its position in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the period. Finally, Colonial Trust Co SC raised its position in shares of Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Positive Sentiment: Q1 results slightly beat expectations: revenue of $5.203B (≈11.6% reported, 9.4% organic) and EPS $0.80 vs consensus $0.79 — a modest operational beat that supports the company’s growth narrative. Boston Scientific announces results for first quarter 2026
Neutral Sentiment: Analysts refreshed estimates ahead of earnings and maintained mostly constructive ratings, but some price targets were trimmed (e.g., Stifel, Truist), leaving upside but signaling caution on near‑term dynamics. Top Wall Street Forecasters Revamp Boston Scientific Expectations Ahead Of Q1 Earnings
Neutral Sentiment: Unusually large call-option activity was observed ahead of the print (heavy call buying), which can amplify intraday volatility but is ambiguous on direction (speculation vs. hedging).
Negative Sentiment: Multiple securities‑class action notices and law‑firm press releases were filed/issued alleging investor harm tied to events in the July 2025–Feb 2026 period; lead‑plaintiff deadlines (May 4) keep litigation headlines in play and elevate headline risk. Pomerantz investor alert
Negative Sentiment: Large institutional reductions and visible insider selling noted in recent filings add to bearish positioning and may pressure sentiment even after a slight beat. Detailed institutional/insider moves were highlighted in market commentary and data summaries.
Negative Sentiment: Shares had already been under pressure into earnings (recent YTD pullback and a 52‑week low reference in media), so the market appears to be de‑risking ahead of and immediately after the print. Blockonomi: 52‑week low coverage

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Down 2.5%

Shares of NYSE BSX opened at $59.46 on Wednesday. Boston Scientific Corporation has a 12-month low of $59.38 and a 12-month high of $109.50. The stock has a market cap of $88.37 billion, a PE ratio of 30.65, a P/E/G ratio of 0.94 and a beta of 0.78. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The company has a 50-day moving average of $69.04 and a 200 day moving average of $86.31.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.45 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of a number of research reports. Wells Fargo & Company cut their target price on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Barclays cut their target price on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday, February 3rd. Sanford C. Bernstein reissued an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. The Goldman Sachs Group cut their target price on shares of Boston Scientific from $98.00 to $93.00 and set a “buy” rating for the company in a research note on Friday, March 27th. Finally, Truist Financial cut their target price on shares of Boston Scientific from $92.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $102.59.

Read Our Latest Analysis on Boston Scientific

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.

Five stocks we like better than Boston Scientific